Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indian Prime Minister Singh Wraps Up U.S. Visit With Agreements In Hand

This article was originally published in PharmAsia News

Executive Summary

WASHINGTON - Indian Prime Minister Manmohan Singh said at the end of his U.S. trip that he and U.S. President Barack Obama discussed several ideas on how the two countries can work together to accelerate global economic recovery

You may also be interested in...



Novavax Looks To Increase Runway Through Strategic Alliance With India’s Cadila Pharma

A recently announced three-prong partnership with India's Cadila Pharmaceuticals should enable Novavax to pay off $22 million in convertible debt due in July and still have about one year's worth of operating cash, the vaccine maker's chief executive, Rahul Singhvi, said in an interview

India Creates Digital Library To Protect Traditional Medicine; Taskforce Pushes To Tap Export Market

NEW DELHI - After the popularity of yoga in the Western world, the Indian government is gearing up to globally promote another piece of the traditional knowledge pie - the Indian system of medicines, which includes Ayurveda, Unani and Siddha (Ayush)

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Latest Headlines
See All
UsernamePublicRestriction

Register

SC070537

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel